Articles
8 June 2009
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
https://doi.org/10.4081/hmr.v2i7.413

Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
221
Views
335
Downloads

Authors

P Montesinos
support@pagepress.org
Tumor lysis syndrome (TLS) can be a life threatening complication during induction chemotherapy in patients with acute myeloid leukemia (AML). TLS is characterized by hyperuricemia, hyperkaliemia, hyperphosphatemia, hypocalcemia and acute renal failure. These abnormalities may occur at presentation of AML due to increased catabolism and turn over of leukemic cells, but more frequently TLS is induced by intensive chemotherapy. Acute urate nephropathy is the main cause of renal failure during TLS, but calcium phosphate precipitation may also contribute to impaired renal function.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.413